Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label Extension

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.0 个研究点目标入组 0 人2007年5月11日

适应症pain MedDRA version: 8.1Level: LLTClassification code 10033371Term: Pain

概览

阶段: 1 期
干预措施: 未指定
疾病 / 适应症: pain
发起方: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
状态: 进行中（未招募）
最后更新: 4年前

概览研究者入排标准结局指标相似试验

概览

简要总结

暂无简介。

注册库

who.int

开始日期

2007年5月11日

结束日期

2007年12月22日

最后更新

4年前

研究类型

Interventional clinical trial of medicinal product

性别

All

研究者

发起方

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

入排标准

入选标准

•Man or woman, between 18 to 80 years of age, inclusive
•Signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
•Physical status rated as \=3 on the American Society of Anesthesiologist (ASA) rating scale (see Attachment 1\)
•Scheduled to undergo standard primary (non\-revision) unilateral total hip replacement surgery due to non\-inflammatory degenerative joint disease (NIDJD).
•Baseline pain intensity \=4 on an 11\-point (0 to 10\) Pain Intensity NRS, rated within 30 minutes before randomization
•Qualifying baseline pain intensity measurements occur within 6 hours of the termination of PCA (after a minimum of 12 hours of PCA), during the postoperative surgical period.
•Must be able to complete all study related procedures and requirements throughout the study period
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes

排除标准

•History of seizure disorder or epilepsy
•Evidence of active infections that may spread to other areas of the body (e.g., osteomyelitis, pyogenic infection of the hip, Hepatitis B or C, or other overt infections) or a history human immunodeficiency virus (HIV) 1 or 2\.
•Acute crystal\-induced arthropathy within the previous 6 months before the screening period of the study
•Has laboratory values reflecting severe renal insufficiency indicated by a creatinine clearance \=30 mg/min.
•Has laboratory values consistent with significant hepatic impairment based on alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values greater than 3 times the upper limit of normal (ULN); or evidence of significant anemia indicated by hemoglobin (Hgb) levels \=8
•Uncontrolled or poorly controlled post\-traumatic stress disorder generalized anxiety disorder (GAD), depression, psychiatric or other significant medical conditions
•Treated with anticonvulsants, monoamine oxidase inhibitors, tricyclic antidepressants, neuroleptics, or serotonin norepinephrine reuptake inhibitor (SNRI) within 2 weeks before screening, (selective serotonin reuptake inhibitor \[SSRI] treatments are allowed if taken for at least 30 days before the screening period of the study at an unchanged dose)
•Treated with a daily opioid analgesic or combination opioid analgesic, other than those containing tramadol or codeine, for more than 30 days before screening
•Contraindications to, history of allergy to, or hypersensitivity to CG5503, Oxycodone, hydromorphone, morphine, or fentanyl, or their excipients.
•Systemic steroid therapy within 3 months before screening, excluding inhalers or a 1\-time intraoperative dose